Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract

Abstract:
PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health.

PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract

Indianapolis, IN | Posted on March 2nd, 2010

The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010. This curative vaccine, which is based on PDS Biotechnology's Versamune™ platform nanotechnology, has demonstrated potent efficacy in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Over 400 million people are infected with the HPV virus and several common cancers are caused by the infection, including cervical, head and neck and anal cancers. No cures exist for these cancers.

The award was based on successful completion of a phase 1 SBIR contract demonstrating efficacy of the drug in human model systems, as well as recent GLP toxicology, pharmacokinetic and bio-distribution studies demonstrating an excellent safety profile and efficient uptake of the drug by the immune system. The new contract will cover over 70% of the costs required to complete the IND-enabling studies. The remaining 30% of the costs will be covered by non-federal government funds.

PDS Biotechnology's Versamune™ nanotechnology platform facilitates efficient uptake of disease-associated proteins and peptides by cells of the immune system and simultaneously acts a strong immune system modulator without the inflammatory side effects induced by current immune stimulators (also known as adjuvants). The result is simple, safe and cost effective drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular disease-related protein formulated with Versamune™. The company's Versamune™-based melanoma product has also demonstrated high efficacy in curing melanoma, which is the most aggressive form of skin cancer, in preclinical animal studies.

This project is funded in part or in whole with Federal Funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN261200900082C. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune™ platform to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
500 Industrial Drive
Suite A
Lawrenceburg, IN 47025
Tel: 812-537-0779
Fax: 812-537-1614

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UT Arlington researchers develop transparent nanoscintillators for radiation detection for medical safety and homeland security September 29th, 2014

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

'Pixel' engineered electronics have growth potential: Rice, Oak Ridge, Vanderbilt, Penn scientists lead creation of atom-scale semiconducting composites September 29th, 2014

Nanomedicine

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

Teijin Aramid’s carbon nanotube fibers awarded with Paul Schlack prize: New generation super fibers bring wave of innovations to fiber market September 25th, 2014

Nanotubes help healing hearts keep the beat: Rice University, Texas Children’s Hospital patch for defects enhances electrical connections between cells September 23rd, 2014

Immune system is key ally in cyberwar against cancer: Rice University study yields new two-step strategy for weakening cancer September 23rd, 2014

Announcements

UT Arlington researchers develop transparent nanoscintillators for radiation detection for medical safety and homeland security September 29th, 2014

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

'Pixel' engineered electronics have growth potential: Rice, Oak Ridge, Vanderbilt, Penn scientists lead creation of atom-scale semiconducting composites September 29th, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Teijin Aramid’s carbon nanotube fibers awarded with Paul Schlack prize: New generation super fibers bring wave of innovations to fiber market September 25th, 2014

New chip promising for tumor-targeting research September 22nd, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Big Results Require Big Ambitions: Three young UCSB faculty receive CAREER awards from the National Science Foundation September 18th, 2014

Nanobiotechnology

Penn Team Studies Nanocrystals by Passing Them Through Tiny Pores September 26th, 2014

Graphene and Amaranthus Superparamagnets: Breakthrough nanoparticles discovery of Indian researcher September 23rd, 2014

New NIH/DOE Grant for Life Science Studies at NSLS-II: Funding will support operation of three powerful experimental stations designed to reveal detailed structures of proteins, viruses, and more September 23rd, 2014

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

New-Contracts/Sales/Customers

Fullerex: Talga Resources Joins INSCX™ Exchange September 4th, 2014

Global Energy Systems Signs Master Sales Agreement with China Aviation Supplies Group September 4th, 2014

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE